

Formulary Exception/Prior Authorization Request Form

Patient Information	Prescriber Information				
Patient Information Patient Name:		Prescriber Information Prescriber Name:			
Patient ID#:					
Address:		Address:			
City:	State:	City:			State:
Home Phone:	ZIP:	Office Pho	one #:	Office Fax #:	ZIP:
Gender: M or F	DOB:	Contact Pe	erson at Doctor	's Office:	
Di	agnosis and M	edical Infori	mation		
Medication:	Strength:	h:		Frequency:	
Expected Length of Therapy:	Qty:	Day Supply:	· .		
Diagnosis:		Diagnosis (ICD) Code(s):			
FORM CANNOT BE EVAL	UATED WITHO	OUT REQUIF	RED CLINICAL	INFORMATION	
What condition is the drug being prescribed for?					
Please list all medications the patient has tried specific to the dia Therapeutic failure, including length of therapy for each					
Drug(s) contraindicated:					
Adverse event (e.g. toxicity, allergy) for each drug:					
Is the request for a patient with one or more chronic conditions (errisk for a significant adverse event with a medication of	e.g., psychiatric on hange? Specify	condition, dia anticipated s	abetes) who is a dignificant adve	stable on the current or rse event:	drug(s) and who might be at high
Does that patient have a chronic condition confirmed by diagnost	tic testing? If so,	please prov	ide diagnostic t	est and date:	
Does the patient have a clinical condition for which other alternat documentation:				hed guidelines or clini	ical literature? If so, please provide
Does the patient require a specific dosage form (e.g., suspension	n, solution, inject	tion)? If so, p	lease provide	dosage form:	
Are additional risk factors (e.g., GI risk, cardiovascular risk, age)	present? If so, p	lease provid	le risk factors: _		
Other: Please provide additional relevant information:					
REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE	ALL RELEVAN	IT CLINICAL	DOCUMENTA	ATION TO SUPPORT	USE OF THIS MEDICATION.
PLEASE COMPLETE CORRESPONDIN	IG SECTION ON	N PAGE 2 FO	OR THE SPEC	IFIC DRUGS/CLASSE	ES LISTED.
FOR ANY DRUG/CLASS NOT LISTED ON PAGE 2, I	PLEASE ATTAC	H ADDITION	NAL INFORMA	TION, BUT CANNOT	EXCEED TWO PAGES.
PRESCRIPTION BENEFIT PLAN MAY REQUEST ADD	ITIONAL INFOR	RMATION O	R CLARIFICAT	ΓΙΟΝ, IF NEEDED, ΤΟ	DEVALUATE REQUESTS.
PLEASE F Expedited/Urgent Review Requested: By checking this box the life or health of the patient or the patient's ability to regain ma		ow, I certify t			e frame may seriously jeopardize
I attest that the medication requested is medically necessary for this pati- information is available for review if requested by CVS/caremark®, the he knowingly makes or causes to be made a false record or statement that i to civil penalties and treble damages under both the federal and state Fa	ealth plan sponsor, is material to a clai	or, if applicab im ultimately p	le, a state or fede aid by the United	eral regulatory agency. I u States government or ar	understand that any person who
Proscriber Signature				Date:	
Prescriber Signature:					
Confidentiality Notice: The documents accompanying this transmission hereby notified that any disclosure, copying, distribution of these docume (via return fax) and arrange for the return or destruction of these docume	ents is strictly prohi				

106-37207A 020416

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

ANTIFUNGALS: Does the patient have a diagnosis of Onychomycosis? Yes or No. If yes, does the infection involve the toenails, fingernails or both? (Please circle) If the diagnosis is Tinea corporis or Tinea cruris, does the patient require systemic therapy or have more extensive superficial infections? Yes or No If the request is for topical medication, has the patient experienced an inadequate treatment response, intolerance or contraindication to an oral antifung therapy? Yes or No
morapy. Too of No
ANTIEMETIC (5-HT3) AGENTS: Is the patient receiving moderate to highly emetogenic chemotherapy or receiving radiation therapy? Yes or No If the patient has a diagnosis of Hyperemesis Gravidarum, is the patient a documented risk for hospitalization for rehydration? Yes or No If the patient has a diagnosis of Hyperemesis Gravidarum, has the patient experienced an inadequate treatment response to two of the following medications? Yes or No If the patient has a diagnosis of Hyperemesis Gravidarum, has the patient experienced an inadequate treatment response to two of the following medications? Yes or No
If yes, please circle two: Vitamin B6, doxylamine, promethazine (Phenergan), trimethobenzamide (Tigan) or metoclopramide (Reglan)
CELEBREX: Is the patient being treated for post-operative pain following CABG surgery or have active GI bleeding? Yes or No Has the patient received a 30-day supply of an anticoagulant, antiplatelet, an oral corticosteroid or a gastrointestinal medication? Yes or No Has the patient had intolerance to or an inadequate treatment response to a traditional NSAID or NSAID/GI combination product? Yes or No Is the drug being prescribed for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, primary dysmenorrheal or juvenile rheumatoid arthritis? Please circle all applicable.
ERECTILE DYSFUNCTION: Does the patient require nitrate therapy on a regular OR on an intermittent basis? Yes or No Is the drug being prescribed for erectile dysfunction? Yes or No Is the drug being prescribed for Pulmonary Arterial Hypertension (PAH)? Yes or No Is the drug being prescribed for symptomatic Benign Prostatic Hyperplasia (BPH)? Yes or No
☐ INSOMNIA AGENTS: Have other treatable medical/psychological causes of chronic insomnia been considered and/or addressed? Yes or No Have appropriate sleep hygiene and sleep environment issues been addressed? Yes or No
PROTON PUMP INHIBITORS: Does the patient have peptic ulcer disease OR frequent and severe symptoms of GERD (e.g., heartburn, regurgitation) OR atypical symptoms or complications of GERD (e.g., dysphagia, hoarseness, erosive esophagitis)? Yes or No Does the patient have Barrett's esophagus or a Hypersecretory syndrome (e.g. Zollinger-Ellison)? Yes or No Is the patient at high risk for GI adverse events? Yes or No
PROVIGIL/NUVIGIL: Does the patient have a diagnosis of Shift Work Sleep Disorder AND experience excessive sleepiness while working? Yes or No Does the patient have a diagnosis of Obstructive Sleep Apnea, and, if so, is the patient currently using a continuous positive airway pressure (CPAP) machine? Yes or No
Does the patient have a diagnosis of Narcolepsy? Yes or No If the patient has a diagnosis of Narcolepsy, has the diagnosis been confirmed by sleep lab evaluation? Yes or No
STIMULANTS: AMPHETAMINES, METHYLPHENIDATES, STRATTERA Does the patient have a diagnosis of ADHD or ADD? Yes or No Has the diagnosis been documented (i.e., evaluated by a complete clinical assessment, using DSM-5, standardized rating scales, interviews/questionnaires)? Yes or No Does the patient have a diagnosis of Narcolepsy? Yes or No If the patient has a diagnosis of Narcolepsy, has the diagnosis been confirmed by sleep lab evaluation? Yes or No
TRETINOIN PRODUCTS: Does the patient have the diagnosis of acne vulgaris or keratosis folliculus? Yes or No
TAZORAC: Does the patient have a diagnosis of acne or plaque psoriasis? Yes or No If the patient is female, has the physician discussed with the patient the potential risks of fetal harm and importance of birth control while using Tazorac? Yes or No
Will the patient be applying Tazorac to less than 20 percent of body surface area? Yes or No
☐ TESTOSTERONE PRODUCTS: Before start of testosterone therapy did the patient (or does the patient currently) have two confirmed low testosterone levels or absence of endogenous testosterone? Yes or No Does the patient have carcinoma of the breast or known or suspected prostate cancer? Yes or No
TRIPTANS: Does the patient have confirmed or suspected cardiovascular or cerebrovascular disease, or uncontrolled hypertension? Yes or No Does the patient have a diagnosis of migraine headache or cluster headache? Yes or No Is the patient currently using migraine prophylactic therapy (e.g., amitriptyline, propranolol, timolol)? Yes or No Has medication overuse headache been considered and ruled out? Yes or No

106-37207A 020416
Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.